Equities

Dawnrays Pharmaceutical (Holdings) Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Dawnrays Pharmaceutical (Holdings) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.18
  • Today's Change0.00 / 0.00%
  • Shares traded196.00k
  • 1 Year change0.00%
  • Beta0.2660
Data delayed at least 15 minutes, as of Feb 13 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

  • Revenue in HKD (TTM)1.26bn
  • Net income in HKD199.86m
  • Incorporated2002
  • Employees1.12k
  • Location
    Dawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
  • Phone+852 21119708
  • Fax+852 21119870
  • Websitehttps://www.dawnrays.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Meilleure Health Intrntnl Indu Grp Ltd38.10m39.17m1.01bn49.0025.830.8327--26.620.00960.00960.00930.29780.02230.03630.9608828,173.902.282.742.603.0272.6447.18102.2728.592.39--0.221141.83-60.81-26.41-20.45---1.03--
3D Medicines Inc507.84m-190.85m1.05bn183.00--1.30--2.07-0.779-0.7792.073.140.37287.536.782,658,870.00-14.79---21.47--92.11---39.68--1.59--0.205---29.81--65.19------
Transcenta Holding Ltd10.66m-301.67m1.08bn171.00--1.33--101.33-0.7445-0.74450.02631.800.00750.37930.492757,909.79-21.21-32.48-30.08-41.1334.7622.08-2,831.15-1,072.370.4387-408.750.2437---79.09-23.9137.24---60.12--
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd1.05bn207.23m1.13bn798.005.460.57674.701.080.36990.36991.873.500.36982.303.341,409,174.007.307.4610.5410.4578.9577.8019.7420.451.42--0.042244.004.716.4124.324.95-8.31--
Beijing Biostar Pharmaceuticals Co Ltd-100.00bn-100.00bn1.37bn147.00------------------------------------------------7.85--24.19------
Dawnrays Pharmaceutical (Holdings) Ltd1.26bn199.86m1.77bn1.12k8.890.47416.001.410.13270.13270.83712.490.28092.477.961,065,846.004.3610.985.0713.7545.7655.5215.5332.764.21--0.002831.01-7.892.2273.2917.2017.132.69
Cutia Therapeutics283.52m-534.89m1.87bn298.00--1.93--6.60-1.70-1.700.90232.670.19082.555.57851,414.80-36.00---44.42--34.92---188.66--2.92--0.2774--103.17--77.91------
Zhaoke Ophthalmology Ltd40.05m-315.22m1.90bn270.00--0.9779--47.34-0.5698-0.56980.07253.540.01591.389.25136,211.20-12.50-38.02-14.65-41.7949.28---787.13-4,412.894.36-29.830.1373--269.73--38.32--18.80--
Jbm (Healthcare) Ltd812.98m216.39m2.29bn412.0010.462.128.232.810.26570.26570.99841.310.51113.765.052,913,918.0014.096.5717.007.8356.7647.8227.5616.602.41--0.248653.4020.6515.4451.2036.9035.96--
Hangzhou Jiuyuan Genetic Biopharm Co Ltd1.48bn139.79m2.32bn1.63k14.821.3012.421.570.64720.64727.247.370.75091.552.17959,578.907.10--8.88--81.67--9.45--4.0346.310.1058--6.35--15.72------
Golden Throat Holdings Group Co Ltd1.11bn303.66m2.32bn842.007.641.706.802.090.41070.41071.501.850.4672.295.321,269,576.0012.7811.7121.0216.7576.4273.0827.3725.871.7321.950.361694.6723.268.2527.3713.71-12.2734.38
Essex Bio-Technology Ltd1.73bn313.18m2.51bn1.43k8.041.106.781.450.55080.55083.054.010.55962.962.841,196,360.0010.1010.2813.5613.6289.5087.7318.0518.701.82--0.113517.49-3.875.4711.610.3101-7.477.14
Jacobson Pharma Corporation Ltd1.53bn302.58m2.54bn1.79k8.361.145.631.660.15190.15190.76981.120.42992.549.06876,757.008.484.8310.296.1744.3041.2619.7314.850.902310.210.28657.097.430.069143.097.0524.0914.87
SinoMab Bioscience Ltd0.00-163.48m2.62bn61.00--8.26-----0.151-0.1510.000.22880.00----0.00-18.46-22.26-24.62-25.68-------3,832.94---7.820.6265--48.42--23.85---0.376--
Data as of Feb 13 2026. Currency figures normalised to Dawnrays Pharmaceutical (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

3.37%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management (Hong Kong) Ltd.as of 31 Oct 202537.04m2.46%
Dimensional Fund Advisors LPas of 30 Nov 202512.55m0.84%
Dimensional Fund Advisors Ltd.as of 30 Nov 2025710.52k0.05%
DFA Australia Ltd.as of 31 Dec 2025212.52k0.01%
Acadian Asset Management LLCas of 31 Dec 202579.49k0.01%
FIL Investments Internationalas of 30 Jun 202576.43k0.01%
American Century Investment Management, Inc.as of 30 Sep 20257.00k0.00%
Velten Asset Management GmbHas of 28 Nov 20250.000.00%
More ▼
Data from 30 Sep 2025 - 28 Nov 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.